- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.07. | Evaxion A/S - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 25.07. | Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 | 265 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will be presenting two-year clinical... ► Artikel lesen | |
| 11.07. | Evaxion finalizes €3.5 million debt-to-equity deal with EIB | 3 | Investing.com | ||
| 11.07. | Evaxion schließt Debt-to-Equity-Vereinbarung mit EIB über 3,5 Millionen Euro ab | 5 | Investing.com Deutsch | ||
| 11.07. | Evaxion A/S - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| EVAXION Aktie jetzt für 0€ handeln | |||||
| 11.07. | Evaxion finalizes agreement with EIB to convert debt into equity | 308 | GlobeNewswire (Europe) | Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion's €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth... ► Artikel lesen | |
| 02.07. | Evaxion A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 01.07. | Evaxion Biotech: Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology platform and portfolio | 322 | GlobeNewswire (Europe) | Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO has commencedThomas Schmidt appointed permanent Chief... ► Artikel lesen | |
| 25.06. | Evaxion entwickelt neuen Impfstoff gegen Gruppe-A-Streptokokken | 6 | Investing.com Deutsch | ||
| 25.06. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.06. | Evaxion Biotech: Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus | 261 | GlobeNewswire (Europe) | Initial computational analysis demonstrated that Evaxion's AI-Immunology platform can identify novel vaccine targets to combat
Group A Streptococcus (GAS)New vaccine program is added to Evaxion's... ► Artikel lesen | |
| 03.06. | Evaxion secures Gates Foundation grant for polio vaccine | 2 | Investing.com | ||
| 03.06. | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.06. | Evaxion Biotech: Evaxion receives grant funding to design new polio vaccine | 342 | GlobeNewswire (Europe) | Evaxion awarded a grant from the Gates FoundationGrant funds research aimed at ultimately eradicating polio, a highly infectious viral diseaseEvaxion will apply its leading AI-Immunology platform to... ► Artikel lesen | |
| 28.05. | H.C. Wainwright maintains Buy on Evaxion Biotech with $14 PT | 2 | Investing.com | ||
| 28.05. | Evaxion targets at least two new business development deals in 2025 while maintaining cash runway to mid-2026 | 3 | Seeking Alpha | ||
| 27.05. | Evaxion reports progress in cancer vaccine trial, extends cash runway | 2 | Investing.com | ||
| 27.05. | Evaxion Biotech: Evaxion announces business update and first quarter 2025 financial results | 350 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/SAbout Evaxion
Evaxion A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction... ► Artikel lesen | |
| 27.05. | Evaxion meldet Fortschritte bei Krebsimpfstoff-Studie und verlängert Finanzierung | 14 | Investing.com Deutsch | ||
| 27.05. | Evaxion Biotech ADS GAAP EPS of -$0.01 | 2 | Seeking Alpha |
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 94,25 | -2,23 % | KI-Aktien: SAP enttäuscht, BioNTech überrascht und NetraMark schlägt ChatGPT! | Schwach präsentiert sich gestern die Aktie von SAP. Dabei läuft es operativ bei der Softwareschmiede rund und beim Ausbau von KI- und Cloud-Geschäft kommt man voran. Bietet sich jetzt eine Chance zum... ► Artikel lesen | |
| EVOTEC | 7,046 | -4,78 % | Fast 200 % Kurspotenzial! Evotec, Plug Power, Empire Brand Building Aktie | Erstmals haben Analysten den Newcomer Empire Brand Building unter die Lupe genommen. Sie sehen bei dem Schweizer Betreiber von Social Media- und E-Commerce-Plattformen für Familien fast 200 % Kurspotenzial.... ► Artikel lesen | |
| QIAGEN | 43,800 | -0,86 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| CUREVAC | 4,742 | +0,30 % | CureVac ÜBERRASCHT Anleger: Insider kaufen massenhaft Anteile - Sofortiges HANDELN erforderlich!!! | ||
| PAION | 0,017 | -16,16 % | Paion Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| AMGEN | 257,25 | -2,46 % | Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial | ||
| NOVAVAX | 5,813 | -2,99 % | Novavax, Inc.: Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study | Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose... ► Artikel lesen | |
| STRYKER | 344,30 | -1,80 % | Dividendenbekanntmachungen (31.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGNC INVESTMENT CORP US00123Q1040 0,12 USD 0,1051 EUR AGREE REALTY CORPORATION US0084921008 0,256 USD 0,2243 EUR ALLIANT ENERGY... ► Artikel lesen | |
| BIOGEN | 111,35 | +0,27 % | Biogen Q2 Results Top Estimates; Boosts FY25 Outlook | WESTON (dpa-AFX) - Biotechnology company Biogen, Inc. (BIIB) reported Thursday that net income attributable to the company for the second quarter grew to $634.8 million or $4.33 per share from... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,200 | -2,57 % | The 3 Things That Matter for CRISPR Therapeutics Now | ||
| OCUGEN | 0,900 | -3,45 % | Ocugen, Inc. - 8-K, Current Report | ||
| MAINZ BIOMED | 1,735 | -9,16 % | MAINZ BIOMED N.V. - F-1, Registration statement for certain foreign private issuers | ||
| RECURSION PHARMACEUTICALS | 5,945 | 0,00 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
| AVIDITY BIOSCIENCES | 36,650 | -0,62 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 5,140 | 0,00 % | Pre-market Movers: VerifyMe, Psyence Biomedical, Pineapple Financial, Align Technology, Confluent | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green VerifyMe, Inc. (VRME) is up over 79% at $1.23.
Psyence... ► Artikel lesen |
EVAXION A/S ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,640 Euro und damit -5,04 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVAXION A/S ADR finden Sie auf Wallstreet Online.